Angelina A. Ushakova, Victor V. Fedotov, Roman A. Drokin, Evgeniy N. Ulomsky, Vladimir L. Rusinov, Alexander A. Spasov, Lyudmila V. Naumenko, Alyona S. Taran, Alina M. Chebanko, Dmitry S. Yakovlev, Maria S. Pshenichnikova
{"title":"3(4)-烷基-[1,2,4]三唑并[1,5-a]嘧啶-7-胺的合成和降眼压特性","authors":"Angelina A. Ushakova, Victor V. Fedotov, Roman A. Drokin, Evgeniy N. Ulomsky, Vladimir L. Rusinov, Alexander A. Spasov, Lyudmila V. Naumenko, Alyona S. Taran, Alina M. Chebanko, Dmitry S. Yakovlev, Maria S. Pshenichnikova","doi":"10.1002/slct.202404243","DOIUrl":null,"url":null,"abstract":"<p>Glaucoma is one of the major causes of irreversible blindness worldwide. Increased intraocular pressure (IOP) is a key factor in the onset and progression of this disease. The drugs used to treat glaucoma influence a variety of biological targets. Azolopyrimidine derivatives have attracted significant attention as potential agents for the treatment of glaucoma because they presumed to be analogs of adenosine receptor (AR) agonists and antagonists. In this study, a series of novel 3(4)-alkyl-[1,2,4]triazolo[1,5-<i>a</i>]pyrimidin-7-amines were synthesized to develop promising ophthalmic hypotensive drugs. The synthesized compounds demonstrated significant hypotensive activity against IOP, which opens new possibilities for glaucoma therapy.</p>","PeriodicalId":146,"journal":{"name":"ChemistrySelect","volume":"9 43","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis and Ocular Hypotensive Properties 3(4)-Alkyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amines\",\"authors\":\"Angelina A. Ushakova, Victor V. Fedotov, Roman A. Drokin, Evgeniy N. Ulomsky, Vladimir L. Rusinov, Alexander A. Spasov, Lyudmila V. Naumenko, Alyona S. Taran, Alina M. Chebanko, Dmitry S. Yakovlev, Maria S. Pshenichnikova\",\"doi\":\"10.1002/slct.202404243\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Glaucoma is one of the major causes of irreversible blindness worldwide. Increased intraocular pressure (IOP) is a key factor in the onset and progression of this disease. The drugs used to treat glaucoma influence a variety of biological targets. Azolopyrimidine derivatives have attracted significant attention as potential agents for the treatment of glaucoma because they presumed to be analogs of adenosine receptor (AR) agonists and antagonists. In this study, a series of novel 3(4)-alkyl-[1,2,4]triazolo[1,5-<i>a</i>]pyrimidin-7-amines were synthesized to develop promising ophthalmic hypotensive drugs. The synthesized compounds demonstrated significant hypotensive activity against IOP, which opens new possibilities for glaucoma therapy.</p>\",\"PeriodicalId\":146,\"journal\":{\"name\":\"ChemistrySelect\",\"volume\":\"9 43\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemistrySelect\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/slct.202404243\",\"RegionNum\":4,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemistrySelect","FirstCategoryId":"92","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/slct.202404243","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Synthesis and Ocular Hypotensive Properties 3(4)-Alkyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amines
Glaucoma is one of the major causes of irreversible blindness worldwide. Increased intraocular pressure (IOP) is a key factor in the onset and progression of this disease. The drugs used to treat glaucoma influence a variety of biological targets. Azolopyrimidine derivatives have attracted significant attention as potential agents for the treatment of glaucoma because they presumed to be analogs of adenosine receptor (AR) agonists and antagonists. In this study, a series of novel 3(4)-alkyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amines were synthesized to develop promising ophthalmic hypotensive drugs. The synthesized compounds demonstrated significant hypotensive activity against IOP, which opens new possibilities for glaucoma therapy.
期刊介绍：
ChemistrySelect is the latest journal from ChemPubSoc Europe and Wiley-VCH. It offers researchers a quality society-owned journal in which to publish their work in all areas of chemistry. Manuscripts are evaluated by active researchers to ensure they add meaningfully to the scientific literature, and those accepted are processed quickly to ensure rapid online publication.
![Synthesis and Ocular Hypotensive Properties 3(4)-Alkyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amines](https://img.booksci.cn/booksciimg/2024-11/99295176541761529668.jpg)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
